Besides the new FDA commissioner, within the past year, there have been significant changes in senior leadership at the agency. These leaders bring new perspectives across a wide range of topics including clinical trials, new product approvals, off-label usage, the role of AI, domestic and international site inspections, etc. Experienced industry professionals will share their opinions as to the opportunities and challenges represented by them and their thoughts as to how things could continue to evolve.